Tag Archives: Cory Kasimov

J.P. Morgan Thinks Moderna Inc’s Stock is Going to Recover

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Moderna Inc (MRNA – Research Report) on August 7 and set a price target of $24. The company’s shares closed on Friday at $13.33, close to its 52-week low of

Allogene Therapeutics Inc (ALLO) Receives a Hold from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics Inc (ALLO – Research Report) on August 7 and set a price target of $29. The company’s shares closed on Friday at $31.18. According to TipRanks.com, Kasimov is

Global Blood Therapeutics (GBT) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) on August 7 and set a price target of $75. The company’s shares closed on Friday at $48.79. According to TipRanks.com, Kasimov is

J.P. Morgan Sticks to Their Buy Rating for Ultragenyx Pharmaceutical, Inc. (RARE)

In a report issued on August 1, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. (RARE – Research Report), with a price target of $75. The company’s shares closed on Friday at $55.66. According to

Analysts Conflicted on These Healthcare Names: Bluebird Bio (NASDAQ: BLUE), Argenx Se (NASDAQ: ARGX) and Ironwood Pharma (NASDAQ: IRWD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bluebird Bio (BLUE – Research Report), Argenx Se (ARGX – Research Report) and Ironwood Pharma (IRWD – Research Report). Bluebird Bio (BLUE) J.P.

BioMarin Pharmaceutical Inc. (BMRN) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin Pharmaceutical Inc. (BMRN – Research Report) on August 2 and set a price target of $133. The company’s shares closed on Friday at $77.84, close to its 52-week low